Glowska-Ciemny Joanna, Szymanski Marcin, Pankiewicz Jakub, Malewski Zbyszko, von Kaisenberg Constantin, Kocylowski Rafal
PreMediCare New Med Medical Center, Poznan, Poland.
Division of Perinatology and Women's Diseases, Poznan University of Medical Sciences, Poznan, Poland.
Ginekol Pol. 2023;94(2):158-166. doi: 10.5603/GP.a2022.0148. Epub 2023 Jan 4.
Alpha-fetoprotein (AFP) is one of the biochemical components of the triple (T-3) and quadruple (T-4) test used so far in prenatal screening mainly for trisomy 21 (T21) and neural tube defects (NTDs). Based on many years of experience and data collected during these studies, a variety of factors have been identified that can affect a pregnant woman's serum AFP level, and thus the risk assessment of trisomy 21 (T21) and neural tube defects. These include both unaccounted for purely medical data (e.g., from baseline information about the patient, assisted reproduction methods used, comorbidities and emerging pregnancy pathologies) and errors made during statistical analysis. Since the triple or quadruple test is usually performed between 15 and 20 weeks of pregnancy, most scientific studies are based solely on results from this period of pregnancy - limited data are available for the first and third trimesters of pregnancy. In the era of new improved screening tests, AFP has the potential to become an independent marker for pregnancy well-being evaluation.
甲胎蛋白（AFP）是目前用于产前筛查的三联（T-3）和四联（T-4）检测的生化成分之一，主要用于筛查21三体综合征（T21）和神经管缺陷（NTDs）。基于多年的经验以及这些研究过程中收集的数据，已确定多种因素会影响孕妇血清AFP水平，进而影响21三体综合征（T21）和神经管缺陷的风险评估。这些因素包括未计入的纯粹医学数据（例如，来自患者的基线信息、所采用的辅助生殖方法、合并症和新出现的妊娠病理情况）以及统计分析过程中出现的误差。由于三联或四联检测通常在妊娠15至20周之间进行，大多数科学研究仅基于该孕期的结果——关于妊娠第一和第三孕期的数据有限。在新型改良筛查检测的时代，AFP有潜力成为评估妊娠健康状况的独立标志物。
